US Patent

US8246979 — Transdermal delivery system for the administration of rotigotine

Method of Use · Assigned to UCB Pharma GmbH · Expires 2027-09-01 · 1y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects an improved transdermal delivery system for administering rotigotine, specifically a self-adhesive matrix that releases the free base form of the drug.

USPTO Abstract

An improved transdermal delivery system (TDS) comprises a self-adhesive matrix comprising a solid or semi-solid semi-permeable polymer which contains rotigotine in its free base form as a multitude of microreservoirs within the matrix. The self-adhesive matrix is highly permeable to the free base of rotigotine and is impermeable to the protonated form of rotigotine.

Drugs covered by this patent

Neupro (ROTIGOTINE) · UCB

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1272`	—	Neupro
`U-1273`	—	Neupro
`U-1272`	—	Neupro
`U-1272`	—	Neupro
`U-1273`	—	Neupro
`U-1272`	—	Neupro

Patent Metadata

Patent number: US8246979
Jurisdiction: US
Classification: Method of Use
Expires: 2027-09-01
Drug substance claim: No
Drug product claim: Yes
Assignee: UCB Pharma GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.